SINT

$2.75

Post-MarketAs of Mar 17, 8:00 PM UTC

Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$2.75
Potential Upside
5%
Whystock Fair Value$2.89
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. ...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$10.59M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.67
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-204.04%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.47

Recent News

Zacks
Nov 10, 2025

Envoy Medical, Inc. (COCH) Reports Q3 Loss, Misses Revenue Estimates

Envoy Medical, Inc. (COCH) delivered earnings and revenue surprises of -29.63% and -23.64%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Nov 6, 2025

Tandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Tops Revenue Estimates

Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of 0.00% and +4.83%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Nov 4, 2025

Neuronetics (STIM) Reports Q3 Loss, Misses Revenue Estimates

Neuronetics (STIM) delivered earnings and revenue surprises of -18.18% and -2.21%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Oct 16, 2025

What Makes SINTX TECHNOLOGIES, INC. (SINT) a Strong Momentum Stock: Buy Now?

Does SINTX TECHNOLOGIES, INC. (SINT) have what it takes to be a top stock pick for momentum investors? Let's find out.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Sep 18, 2025

Several Insiders Invested In Sintx Technologies Flagging Positive News

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.